I hope no one listened to this thread regarding shorting CYGN. If ya did, ya shouldn't have. I hope you didnt listen to these posts:
To: yields (4304 )
From: Auric Goldfinger
Friday, Dec 3 1999 3:21PM ET
Reply # of 4327
AMPD, your welcome. CYGN going into FDA panel on Monday. Ain't gonna happen.
Back up ze truck.
-or this one-
To: EtTuBrute (4309 )
From: Auric Goldfinger
Friday, Dec 3 1999 9:23PM ET
Reply # of 4327
CYGN: No & No. However I was a seed investor in Medisense and made a pile of dough
when we sold it to Baxter. Ergo, I know the space VERY well. Probabalistically, you &
CYGN are toast.
FDA wants 10% accuracy, clinical trials showed 15% & that would imply normal home
use of say 25%. Doubt me at your financial peril, Jr.
HERE IS OFFICIAL NEWS:
Monday December 6, 6:29 pm Eastern Time
FDA panel backs Cygnus diabetes glucose monitor
GAITHERSBURG, Md., Dec 6 (Reuters) - Federal advisers on Monday backed a watch-like
device by Cygnus Inc. (NasdaqNM:CYGN - news) designed to help diabetics keep better
track of changes in their blood sugar.
A Food and Drug Administration advisory panel voted unanimously that the GlucoWatch was
safe and effective for sale in the United States. The committee's support is important because
the FDA usually follows the advice of its panels.
Cygnus said the device could provide painless measurements of blood sugar, or glucose, every 20 minutes for up to 12 hours.
Better glucose information can help patients and their doctors adjust treatments to improve management of the disease.
Nearly 16 million Americans have diabetes, which can lead to serious complications such as blindness, limb loss and kidney
damage.
Cygnus, based in Redwood City, Calif., recently announced it would sell most of the assets from its drug delivery business to a
Johnson & Johnson unit and focus on developing the GlucoWatch. |
